PE20242109A1 - Formas puras de aticaprant cristalino - Google Patents
Formas puras de aticaprant cristalinoInfo
- Publication number
- PE20242109A1 PE20242109A1 PE2024001920A PE2024001920A PE20242109A1 PE 20242109 A1 PE20242109 A1 PE 20242109A1 PE 2024001920 A PE2024001920 A PE 2024001920A PE 2024001920 A PE2024001920 A PE 2024001920A PE 20242109 A1 PE20242109 A1 PE 20242109A1
- Authority
- PE
- Peru
- Prior art keywords
- aticaprant
- crystalline
- pure forms
- pure
- solvates
- Prior art date
Links
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical compound CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 title abstract 4
- 229940121408 aticaprant Drugs 0.000 title abstract 4
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20242109A1 true PE20242109A1 (es) | 2024-10-28 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001920A PE20242109A1 (es) | 2022-03-07 | 2023-03-06 | Formas puras de aticaprant cristalino |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (enExample) |
| EP (1) | EP4489748A1 (enExample) |
| JP (1) | JP2025508071A (enExample) |
| KR (1) | KR20240158951A (enExample) |
| CN (1) | CN119156210A (enExample) |
| AU (1) | AU2023231493A1 (enExample) |
| CA (1) | CA3254503A1 (enExample) |
| CL (1) | CL2024002643A1 (enExample) |
| CO (1) | CO2024012457A2 (enExample) |
| IL (1) | IL315411A (enExample) |
| JO (1) | JOP20240195A1 (enExample) |
| MX (1) | MX2024010978A (enExample) |
| PE (1) | PE20242109A1 (enExample) |
| TW (1) | TW202345795A (enExample) |
| WO (1) | WO2023170547A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CA3254546A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709522B2 (en) * | 2008-01-22 | 2010-05-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| WO2022234457A1 (en) * | 2021-05-04 | 2022-11-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023231493A1 (en) | 2024-10-24 |
| WO2023170547A1 (en) | 2023-09-14 |
| EP4489748A1 (en) | 2025-01-15 |
| JOP20240195A1 (ar) | 2024-09-05 |
| CO2024012457A2 (es) | 2024-09-30 |
| CL2024002643A1 (es) | 2025-01-24 |
| CA3254503A1 (en) | 2023-09-14 |
| TW202345795A (zh) | 2023-12-01 |
| MX2024010978A (es) | 2024-12-06 |
| US20230348377A1 (en) | 2023-11-02 |
| US20250326714A1 (en) | 2025-10-23 |
| CN119156210A (zh) | 2024-12-17 |
| KR20240158951A (ko) | 2024-11-05 |
| IL315411A (en) | 2024-11-01 |
| JP2025508071A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012457A2 (es) | Formas puras de aticaprant cristalino | |
| MX2022007576A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2023007852A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| MX2020012028A (es) | Metodos y composiciones para tratar el cancer. | |
| PY2155927A (es) | Mezclas fungicidas | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| CR20250159A (es) | Derivados de n–acriloilmorfolina como moduladores de keap1 y sus usos | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| MX2025006791A (es) | Agente de iarn con nucleótidos modificados | |
| JOP20230157A1 (ar) | طرق مُعالجة فيروس كورونا | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| CL2024003587A1 (es) | Inhibidores de mek y usos de estos | |
| CO2021014747A2 (es) | Métodos para el tratamiento de βeta-talasemia | |
| MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
| CL2025003307A1 (es) | Inhibidores de mrgprx2 y sus métodos de uso. | |
| MX2024003981A (es) | Composiciones para iluminar y metodos de uso. | |
| MX2021013117A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CO2024010384A2 (es) | Formas cristalinas de 3-(5-(2-hidroxi-2-metilpropoxi)-6-metilpirazin-2-il)-1h-indol-7-carbonitrilo |